drugset
drugset / Trial / NCT02871297

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

NCT02871297 ↗

Phase 3 Terminated 662 enrolled H. Lundbeck A/S
NaSingle-groupOpen-labelTreatment

Summary

Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent participants with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD.

Timeline

Start
2016-08-17
Primary completion
2022-03-25
Completion
2022-04-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Vortioxetine Unknown 5 mg Oral
Subject Vortioxetine Unknown 10 mg Oral
Subject Vortioxetine Unknown 15 mg Oral
Subject Vortioxetine Unknown 20 mg Oral

Indications

major depressive disorder